B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments

• Published in: International journal of molecular sciences Vol. 20; no. 24; p. 6231
• Main Authors: Yap, Desmond Y. H., Chan, Tak Mao
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10.12.2019; MDPI
• Subjects: Antibodies; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antigens; Azathioprine - pharmacology; Azathioprine - therapeutic use; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; B-Lymphocytes - pathology; Bone marrow; Cell growth; Clinical Trials as Topic; Cyclophosphamide - pharmacology; Cyclophosphamide - therapeutic use; Cytokines; Genes; Homeostasis; Humans; Immunoglobulins; Immunology; Immunosuppressive Agents - pharmacology; Immunosuppressive Agents - therapeutic use; Ligands; Lupus; Lupus Erythematosus, Systemic - drug therapy; Lupus Erythematosus, Systemic - immunology; Lupus Erythematosus, Systemic - pathology; Lupus Nephritis - drug therapy; Lupus Nephritis - immunology; Lupus Nephritis - pathology; Lymphocytes; Mycophenolic Acid - pharmacology; Mycophenolic Acid - therapeutic use; Pathogenesis; Patients; Plasma; Review; Transcription factors; Transgenic animals; pathogenesis; treatment; lupus nephritis; systemic lupus erythematosus; B cell abnormalities
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20246231

Abnormalities in B cells play pivotal roles in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). Breach in central and peripheral tolerance mechanisms generates autoreactive B cells which contribute to the pathogenesis of SLE and LN. Dysregulation of B cell transcription factors, cytokines and B cell–T cell interaction can result in aberrant B cell maturation and autoantibody production. These immunological abnormalities also lead to perturbations in circulating and infiltrating B cells in SLE and LN patients. Conventional and novel immunosuppressive medications confer differential effects on B cells which have important clinical implications. While cyclophosphamide and mycophenolate mofetil (MMF) showed comparable clinical efficacy in active LN, MMF induction was associated with earlier reduction in circulating plasmablasts and plasma cells. Accumulating evidence suggests that MMF maintenance is associated with lower risk of disease relapse than azathioprine, which may be explained by its more potent and selective suppression of B cell proliferation. Novel therapeutic approaches targeting the B cell repertoire include B cell depletion with monoclonal antibodies binding to cell surface markers, inhibition of B cell cytokines, and modulation of costimulatory signals in B cell–T cell interaction. These biologics, despite showing improvements in serological parameters and proteinuria, did not achieve primary endpoints when used as add-on therapy to standard treatments in active LN patients. Other emerging treatments such as calcineurin inhibitors, mammalian target of rapamycin inhibitors and proteasome inhibitors also show distinct inhibitory effects on the B cell repertoire. Advancement in the knowledge on B cell biology has fueled the development of new therapeutic strategies in SLE and LN. Modification in background treatments, study endpoints and selective recruitment of subjects showing aberrant B cells or its signaling pathways when designing future clinical trials may better elucidate the roles of these novel therapies for SLE and LN patients.